NanoPAL™ and Me : Release Your Worries
and Be Free

Learn more

NanoPAL™ and Me : Release Your Worries
and Be Free

Learn more

When Chest Pain/ Shortness of Breath Strikes

Pneumonia

e.g., flu, COVID-19 or other viral infection

 

Hearrt disease

e.g., acute myocardial infraction, unstable angina, or acute heart failure

Clots

e.g., pulmonary embolism


Non-malignant conditions

e.g., anxiety or post strenuous exercise

 

Pneumonia

e.g., flu, COVID-19 or other viral infection

 

Non-malignant conditions

e.g., anxiety or post strenuous exercise

Heart diseases

e.g., acute myocardial infraction, unstable angina, or acute heart failure

Clots

e.g., pulmonary embolism


Should we drive to the ER immediately and lose a night of sleep
or take a risk and wait until morning to call a physician?

Unnecessary ER Visits and Hospitalization due to Chest PainBreathlessness

>3 billion

in annual hospital
expenditures due to chest pain

+90% of ER visits chest pain accounts for could be reduced

>4 million

of emergency room visits per year
due to dyspnea

+80% of ER visits due to dyspnea does not require hospital admission

ER services

Cost up to 12 times as much as a regular physicuan's visit

Cost the heath system more than 32 billion each year

Our Solution

Our home testing solution provides an alternative scenario that may spare the sick patient a drive to the ER, long waits of at least 2-hours, duplicative testing and wildly inflated bills.


By utilizing a portable home reader, NanoPAL™ together with our ultra-sensitive immunosensor technology, SeraParma™ home tests help analyze multiple biomarker testing results and assist telehealth physicians in determining the crucial next steps for a sick patient.

Shifting the current healthcare expenditure from cure to prevention

On average, the annual total medical costs for heart failure care were estimated at $24,383 per patient, $22,528-32,345 per patient for acute coronary syndrome, and $15,000-40,000 per patient for pulmonary embolism. The majority of those costs were appropriated due to hospitalizations. With our home test solution, patients can test for the relevant biomarkers and communicate with their telehealth physicians, at less than 10% of the average annual total medical costs associated with these diseases.

SeraParma™ : An Accurate and Astute Technology Platform for Early Disease Diagnosis

High-accuracy Early Antibody Rapid Detection

 

The only 3-step rapid test that can detect IgM on the first day upon showing symptoms. All it takes is 3 simple steps, one drop of blood and 15 minutes

 

 

Innovative Nanoparticle Signal Amplification Technology

1,000 times more sensitive than rapid tests that are currently available, SeraParma™ can detect early infection(as early as the first day after symptom onset) with zero false negative

Clinical validation Shows 100% Sensitivity, 100% Specificity

100% agreement between PCR and SeraParma™ testing results from 241 samples

 

 

 

 

The Only High-specificity Rapid Test with Wash Buffer

 

The unique rapid test with wash buffer greatly increases specificity with zero false positive

 

 

 

 

  • +886-2-7768-9655

  • service@nanoparma.com

@ 2022 NanoParma Biomedical, LLC.

Contacts

  • +886-2-7768-9655

  • service@nanoparma.com

@ 2022 NanoParma Biomedical, LLC.

Learn how Our disease health management works to benefit others

We aim to establish a business model that benefits various health care stakeholders: beneficiaries include health plan payers, ambulatory care/telehealth providers, and patients. By reimbursing our test solutions, unnecessary ER visits and hospitalizations will be reduced thereby reducing the costly co-payments paid by patients. By introducing our test solutions to ambulatory care and telehealth providers, reduced turnaround times for test results and diagnostic decisions will improve overall patient outcomes. By having our home testing solution at hand, patients and their telehealth physicians are able solve any issues at home without needing to rush to the ER only to wait for another 2 hours for the same testing result they could have obtained at home. In addition to our handy home tests and reader, we will also provide a comprehensive disease and lifestyle management platform online for patients. This service will help patients better understand their prognosis of disease and likely prevent them from worsening.

Patients’ life quality can be improved without hospitalization and unnecessary concerns about false alarms. Ambulatory care and telehealth providers can resolve most patients’ problems in non-hospital settings. The healthier the insured is, the more profitable the insurer is. Therefore, the payers will be more willing to reimburse home tests and disease management solutions, shifting the current healthcare expenditure from cure to prevention.